ABC | Volume 112, Nº4, April 2019

Original Article de Faria et al Inflammatory score and resistant hypertension Arq Bras Cardiol. 2019; 112(4):383-389 1. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis . Endocrinology. 2003;144(6):2195-200. 2. Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism. 2013;62(11):1543-52. 3. Briones AM, Aras-López R, Alonso MJ, Salaices M. Small artery remodeling in obesity and insulin resistance. Curr Vasc Pharmacol. 2014;12(3):427-37. 4. Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, and chronic kidney disease . Int J Nephrol RenovascDis. 2014 Feb 18;7:75-88. 5. deFariaAP,DemacqC,FigueiredoVN,MoraesCH,SantosRC,SabbatiniAR, et al. Hypoadiponectinemia and aldosterone excess are associatedwith lack of blood pressure control in subjects with resistant hypertension . Hypertens Res. 2013;36(12):1067-72. 6. Sabbatini AR, Faria AP, Barbaro NR, Gordo WM, Modolo RG, Pinho C, et al. Deregulation of adipokines related to target organ damage on resistant hypertension . J HumHypertens. 2014;28(6):388-92. 7. Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, Fonseca FH, et al. Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers. Blood Press. 2015;24(1):7-13. 8. Cortez AF, Muxfeldt ES, CardosoCR, Salles GF.Prognostic value of C-reactive protein in resistant hypertension . Am J Hypertens. 2016;29(8):992-1000. 9. Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophywith systemic inflammation and endothelial damage in resistant hypertension . Hypertension. 2007;50(4):723-8. 10. ChenH, Montagnani M, Funahashi T, Shimomura I, QuonMJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells . J Biol Chem. 2003;278(45):45021-6. 11. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-6. 12. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway . Circulation. 2000;102(11):1296-301. 13. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. BiochemBiophys Res Commun. 2003;301(4):1045-50. 14. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 1996;97(9):2152-7. 15. Machleidt F, Simon P, Krapalis AF, Hallschmid M, Lehnert H, Sayk F. Experimentalhyperleptinemiaacutely increasesvasoconstrictorysympathetic nerveactivityinhealthyhumans.JClinEndocrinolMetab.2013;98(3):E491-6. 16. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement fromtheAmericanHeartAssociationProfessionalEducationCommitteeofthe CouncilforHighBloodPressureResearch.Hypertension.2008;51(6):1403-19. 17. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. 18. de SouzaWA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar-Toledo JC, MorenoH. Intensivemonitoring of adherence to treatment helps to identify “true”resistanthypertension.JClinHypertens(Greenwich).2009;11(4):183-91. 19. de Haro Moraes C, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T, et al. High-circulating leptin levels are associatedwith increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens. 2013;27(4):225-30. 20. Boer-Martins L, Figueiredo VN, Demacq C, Martins LC, Consolin-Colombo F, Figueiredo MJ, et al. Relationship of autonomic imbalance and circadian disruptionwith obesity and type 2 diabetes in resistant hypertensive patients. Cardiovasc Diabetol. 2011 Mar 22;10:24. 21. Catharina AS, Modolo R, Ritter AMV, Sabbatini AR, Lopes HF, Moreno Junior H,FariaAP.MetabolicSyndrome-RelatedFeatures inControlledandResistant Hypertensive Subjects. Arq Bras Cardiol. 2018 Jun;110(6):514-521. 22. Enkhmaa B, Anuurad E, Zhang W, Kim K, Berglund L. Diverging trajectory patterns of systemic versus vascular inflammation over age in healthy Caucasians and African-Americans . Atherosclerosis. 2015;239(2):509-15. 23. Filho AG, Kinote A, Pereira DJ, Rennó A, dos Santos RC, Ferreira-Melo SE, et al. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats. Eur J Pharmacol. 2013;700(1-3):201-9. 24. Kirabo A, Fontana V, de Faria AP, Loperena R, Galindo CL, Wu J, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124(10):4642-56. References revision of the manuscript for intellectual content: de Faria AP, Ritter AMV, Gasparetti CS, Corrêa NB, Brunelli V, Almeida A, Pires NF, Modolo R, Moreno Junior H; statistical analysis: de Faria AP, Modolo R; obtaining funding: de Faria AP, Ritter AMV, Moreno Junior H. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding This study was supported by the São Paulo Research Foundation (FAPESP), the National Council for Scientific and Technological Development (CNPq); and Coordination for the Improvement of Higher Education Personnel (CAPES), Brazil. Study Association This study is not associatedwith any thesis or dissertationwork. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Faculdade de Ciências Médicas da Universidade Estadual de Campinas under the protocol number 188.161/2013; CAAE: 11189712.8.0000.5404. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 388